Genmab Reports European Commission Approval Of TEPKINLY (epcoritamab) For Adults With Relapsed Or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Portfolio Pulse from Benzinga Newsdesk
Genmab has received approval from the European Commission for TEPKINLY (epcoritamab) for adults with relapsed or refractory Diffuse Large B-cell Lymphoma. TEPKINLY is the first and only subcutaneous T-cell engaging bispecific antibody approved for this treatment in the EU, Liechtenstein, Norway, and Iceland.
September 25, 2023 | 11:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genmab's TEPKINLY has been approved by the European Commission, potentially increasing the company's market share and revenues in the EU and other regions.
The approval of TEPKINLY by the European Commission opens up a new market for Genmab. This could lead to increased sales and revenues for the company, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
While ABBV is mentioned in the article, there is no specific news or information provided that would impact the company's stock.
ABBV is mentioned in the article, but there is no specific news or information provided that would impact the company's stock. Therefore, the short-term impact on ABBV's stock is neutral.
CONFIDENCE 100
IMPORTANCE 10
RELEVANCE 20